AmacaThera Closes US$3.6M Seed Financing Round
AmacaThera Inc. is pleased to announce the closing of its US$3.6M seed financing round. A first close of the round was led by Sprout BioVentures/ Viva Biotech with participation from Grey Sky Venture Partners, and the round was recently completed with an investment by Toronto-based Lumira Ventures.
RetiSpec Technology Featured in Globe and Mail
This week, the Globe & Mail reported how RetiSpec's retinal scan has the potential to detect patterns specific to Alzheimer's disease even before symptoms develop using a specialized camera and software that analyzes how light reflects off the back of a person's eye.
Reviewing OBIO's Primary Market Research Workshop
Last week OBIO hosted Gary Svoboda (CEO, Adventus Research + Consulting) who provided the audience practical steps they can use to validate technology with primary market research.
OBIO at MedTech Conference in Boston
This year's AdvaMed MedTech Conference in Boston was a fantastic event. OBIO was in attendance for meetings and conversations with US and global investors and strategics about what's coming up for the health science industry in Canada. There was tons of enthusiasm and interest to capitalize on as we head into 2020.
Recap: OBIO CAAP Alumni Group Dinner
On September 17th, OBIO held a dinner to bring together CAAP and CAAP Alumni companies. OBIO would like to thank everyone who came out and joined us to discuss common experiences, challenges and what's coming next.
Reviewing OBIO at RESI Boston
On September 10th, OBIO organized a cross-border networking event in Boston at the Consulate General of Canada. The event was supported by the Consulate General and law firms Fasken and Choate. Over 45 investors, strategics, as well as executives from high potential Canadian health science companies packed the Canada Room at the Consulate and resulted in numerous investor-company interactions.
Apply for the Genomic Applications Partnership Program (GAPP)
Ontario Genomics is pleased to announce that a new round of Genome Canada’s Genomic Applications Partnership Program (GAPP) is now open (Round 18). The program provides a unique opportunity for Receptor organizations to collaborate with an ’omics researcher, and to leverage their R&D investments with public funding.
Application deadline: October 28, 2019
Interface Biologics Announces Sale of Surface Modification Business to Evonik
Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of innovative material science technologies for Medtech and Pharmaceutical applications, is pleased to announce the sale of its surface modification business to Evonik, a German based specialty chemical company with revenues in excess of €13 billion in 2018.
Venture capital has strongest first half on record, with $2.15-billion raised
This week, the Globe & Mail reported that venture-capital investment surged to its strongest first half on record, injecting $2.15-billion into Canadian startups and scale-ups, according to the Canadian Venture Capital & Private Equity Association (CVCA).
FedDev Ontario announces $6.24 million investment in OBIO
FedDev Ontario is investing up to $6.24 million for the Ontario Bioscience Innovation Organization (OBIO®) to boost investment, market access and mentorship opportunities for companies across southern Ontario looking to commercialize their medical innovations.
iMerciv Accepted into CTA Silicon Valley Fall 2019 Cohort
iMerciv was accepted into the Fall 2019 Cohort of the Canadian Technology Accelerator in Silicon Valley, which helps high-potential Canadian technology companies access the unique resources of Silicon Valley to grow at a global scale.
Profound Medical Announces U.S. FDA 510(k) Clearance for TULSA-PRO®
Profound Medical announced that they have received 510(k) clearance from the U.S. Food and Drug Administration to market TULSA-PRO® for ablation of prostate tissue.
Reviewing 'In-Licensing from Tech Transfer Offices: Terms, Tips & Impact on Investability'
On August 21st, OBIO hosted Norton Rose Fulbright’s Anthony de Fazekas (Partner, Head of Technology & Innovation) and Vanessa Grant (Partner), Lumira Ventures’ Jacki Jenuth (Partner), and University of Toronto’s Karen Temple (Commercialization Manager) who discussed practical considerations for licensing health science technologies from tech transfer offices, and how these agreements can impact a company’s future investability.
Able Innovations Named Lion's Lair Finalist
Able Innovations will be pitching live against 9 other companies for a chance to win up to $75,000 in cash prizes at the Lions Lair.
Perimeter Medical Imaging Closes Oversubscribed $C4.4M Financing
Perimeter Medical Imaging announce the completion of a pre-public financing round raising $C4.4million.
Register for the Medventions Lecture Series
Hosted by Sunnybrook, this flagship weekly lecture series features enlightening talks on key topics related to pursuing medical technology innovation, commercialization and entrepreneurship, aimed at clinicians, engineers and life sciences researchers and trainees.
Apply to the Women Founders Fund
The Women Founders Fund aims to bridge the gap on entrepreneurial equal opportunity by providing access to resources and empowering growth for female entrepreneurs.
Apply for a RBC Post-Doctoral and Graduate Fellowship
The RBC Post-Doctoral & Graduate Fellowships will support research and innovation at the University of Toronto and recognize emerging leaders who are establishing a record of research, scholarship, and impact, and exhibit the potential to make significant contributions to the body of research in the field of entrepreneurship and innovation.
Adrenalease, Cheelcare, Braze Mobility & CoHealth Named 43North Semi-Finalists
Founded in 2014, 43North is a startup competition with prizes of $5M USD in investment, dedicated mentorship and free incubator space in Buffalo, NY.
Steadiwear Announces FDA Registration and Pre-Order
Steadiwear announced that they received FDA registration and that the Steadi-One is now available for pre-order.